Glucocorticoid (GC) resistance is a significant problem in the management of lymphoid malignancies. We have previously shown that modulation of intra-cellular cyclic-AMP via inhibition of phosphodiesterase 4B (PDE4B) induces apoptosis in diffuse large B-cell lymphomas (DLBCL). Here, we show that overexpression of PDE4B in DLBCL impinge on the same genes/pathways that are abnormally active in GC-resistant tumors. In agreement with these data, we demonstrated, in vitro and in vivo, that genetic and pharmacological targeting of PDE4B restores the GC sensitivity in B cell lymphomas, in association with cyclic-AMPmediated inhibition of mTOR. A marked correlation between PDE4B levels and AKT-mTOR activity in primary DLBCLs confirmed the relevance of this interplay. Together, our data indicate that PDE4 inhibitors may be useful in the treatment of lymphoid malignancies, mechanistically explain how these agents could improve GC sensitivity, and demonstrate that insights into disease pathogenesis can be exploited to rationally overcome drug resistance. 
INTRODUCTION
In recent years, it has become apparent that the successful development of novel therapeutic approaches for the treatment of cancer needs to be guided by an improved understanding of disease pathogenesis. While these rational strategies have recently yielded important results(1), they are only rarely conceived with emphasis on overcoming acquired or innate resistance to pharmacological agents that are already part of the therapeutic armamentarium. In this context, a pressing issue is the identification and validation of strategies aimed at improving or reestablishing glucocorticoid (GC) sensitivity in lymphoid malignancies. This is an important goal because GCs remain an important agent in the treatment of these tumors and, despite all advances in the molecular classification of these entities (2) (3) (4) , the in vitro and in vivo responses to GCs continues to be one of the determinants of clinical outcome, in particular in acute lymphoid leukemia and multiple myeloma(5-7).
Cyclic-AMP (cAMP) is a ubiquitous second messenger with marked growth inhibitory and proapoptotic properties in lymphocytes (8) (9) (10) (11) . At the termination point, the intracellular levels of cAMP are controlled by phosphodiesterases (PDE). In immune cells, members of the PDE4 family, particularly PDE4B in B-lymphocytes, account for most of the cAMP hydrolysis and inactivation (12) . This feature, combined with pharmacological and structural principles that make phosphodiesterases excellent drug targets, prompted the testing of PDE4 inhibitors for inflammatory conditions such as asthma and chronic obstructive pulmonary disease (COPD) (13) .
Research.
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Author Manuscript Published OnlineFirst on July 8, 2011; DOI: 10.1158/1078-0432.CCR- We previously showed that PDE4B expression was significantly elevated in patients with fatal diffuse large B-cell lymphoma (DLBCL) (4, 9) . Subsequently, using in vitro genetic and pharmacological modulation of PDE4B activity, we confirmed that this enzyme abrogates the growth inhibitory effects of cAMP in DLBCL, explaining why elevated PDE4B expression contributes to the poor outcome of subsets of B cell tumors (9, 11) . These data pointed to the potential of PDE4 inhibitors as anti-lymphoma agents, and highlighted the addiction of subsets of DLBCL to low cAMP levels. Importantly, in these initial investigations we uncovered an interplay between cAMP/PDE4B and the PI3K/AKT pathway in DLBCL, whereby cAMPinduced apoptosis was found to be dependent on the downmodulation of this growth promoting pathway.
Recently, an unbiased chemical genomic approach unveiled a critical role for the AKT/mTOR pathway in modulating GC resistance in acute lymphoid leukemia (ALL) (14) . These observations led us to put forward the novel hypothesis that the cAMP-mediated downregulation of AKT could significantly influence GC response, and that PDE4B inhibition may restore GC sensitivity in malignant lymphocytes. Herein, we comprehensively examined this hypothesis and show that, i) high expression of PDE4B in primary DLBCL impinges on the same genes and pathways associated with GC resistance in ALL, ii) PDE4B expression directly correlates with GC resistance in B cell lymphomas, iii) genetic models of gain and loss of function for PDE4B sensitivity in B-cell lymphomas, in vitro and in vivo. Importantly, we showed that the correlation between PDE4B expression and AKT/mTOR activity was also present in primary DLBCL.
Together, these data link PDE4B to AKT/mTOR mediated GC resistance, mechanistically explain how elevation of intracellular cAMP levels improves GC sensitivity, and provide further pre-clinical support for expanding the testing of PDE4 inhibitors in lymphoid cancers.
MATERIALS AND METHODS
Cell Lines, primary tumors and normal B cells. Human DLBCL cell lines (DHL6, DHL7, DHL10, Ly1)(15, 16), Ramos (human Burkitt lymphoma cell line), were cultured in RPMI 1640 (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Hyclone), 100U/mL penicillin, 100 µg/mL streptomycin, 2mM L-glutamine, and 10mM N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES) buffer in a 5% humidified CO 2 incubator at 37 o C, as previously reported (11) . The HEK293 cell line was cultured in DMEM supplemented as described above. The DLBCL cell line Ly3 was grown in IMDM supplemented with 20% human serum, as we described (9) . The primary DLBCLs were obtained from our tumor bank and reported before (17) ; the detailed features of the samples used in this study are described in Supplementary Table 3 . These studies were approved by the institutional review board of the University of Texas Health Science Center at San Antonio (UTHSCSA). Murine mature B cells were isolated and purified (>90% purity) from wild-type C57BL/6 mice spleens as we recently described (11) , and according to approval from the Institutional Animal Care and Use Committee (IACUC) of the University of Texas Health Science Center at San Antonio.
Research. Gene Set Enrichment Analysis (GSEA). A gene collection containing 101 probe sets expressed at significantly higher levels in GC-resistant than in GC-sensitive ALL samples (14) were analyzed within the context of a cohort of primary DLBCL (n=56) previously investigated by gene expression profiling on microarrays (18). PDE4B expression below and above the median, analysis according to the manufacturer's guidelines (Apoptosis Detection Kit I; BD Biosciences, San Diego, CA) and propidium iodide (Sigma-Aldrich) staining also followed by FACS, as we described (9) . In these assays, the relevant cell lines were cultured either in FBS or human serum containing media, and data were collected at 48h, 72h or 96h. Specific details on culture knockdown was performed with PDE4B-specific q-RT-PCR, as we described (9, 11) . Expression of the glucocorticoid receptor (GR) in these cell models was determined by q-RT-PCR, at baseline and following exposure to forskolin, using primers that amplify all GR isoforms (GR Excel software (Microsoft). Dose-effect curves were calculated with the CalcuSyn software (Biosoft, Cambridge, UK) and used to generate the combination index (CI), reflecting the synergistic activity of the drugs tested.
RESULTS
A gene expression signature shared by DLBCL expressing high levels of PDE4B, and ALL resistant to glucocorticoid. We showed that PDE4B activity controls PI3K/AKT signals in DLBCL(9) whereas Wei at al. independently determined that the AKT/mTOR pathway regulate GC sensitivity in ALL (14) Together, these data led us to hypothesize that PDE4B, by regulating the inhibitory effects of cAMP towards AKT, may play an important role in the resistance to GCs found in subsets of lymphoid cancers. We reasoned that if this hypothesis was correct, PDE4B expression should impinge on the same genes/pathways that control GC response in malignant lymphocytes, and that the gene signatures of GC resistance and PDE4B overexpression should be related, even if determined in distinct tumor types. To test this concept, we used gene set enrichment analysis (GSEA) (20) and found a significant enrichment of "GC resistance" genes in the expression signature of PDE4B-high DLBCLs (FDR=0.19) ( Figure 1A and Supplementary Table 1) . Figure 1A) , which is highly correlated with previously defined protein expression(9). As we have reported before (9, 11) , these cell lines present with low basal activity of adenylyl cyclase and, without proper stimulation, lack intracellular cAMP. Thus, to fully capture the relevance of PDE4B activity in this context, we experimentally increased intracellular cAMP with the adenylyl cyclase activator forskolin or with the cell permeable synthetic cAMP, 8-Br-cAMP.
Examining five independent B cell lymphoma cell lines, we found that in presence of cAMP, tumors expressing low levels of PDE4B were markedly more sensitive to dexamethasoneinduced apoptosis than lymphomas expressing high PDE4B levels (p<0.05 one-way ANOVA test) ( Figure 1B To further define the relationship between cAMP/PDE4B, AKT/mTOR and GC sensitivity in B cell lymphomas, we also determined the phosphorylation levels of AKT and two mTORregulated proteins in our model. As shown in Figure 1C markers for mTOR inhibition) in a PDE4B-dependent manner. Furthermore, we showed that the cAMP-mediated downregulation of this pathway is readily detectable in normal mature B cells (Supplementary Figure 1G) , thus defining the physiologic relevance of these signals, and highlighting the role of the abnormally high PDE4B expression in blocking this growth inhibitory axis in B cell lymphomas.
In addition, as recent data have suggested a correlation between the pre-treatment levels of the anti-apoptotic protein MCL1 and GC response in MLL-translocated ALLs (21), we also measured the expression of this anti-apoptotic protein in our lymphoma models. In the group of cell lines analyzed, MCL1 baseline expression did not per se predicted GC response (Supplementary Figure 1H) , although, as we will show below, MCL1 can be downregulated by cAMP in a PDE4B and AKT dependent fashion. Finally, c-MYC expression has been suggested to influence GC sensitivity in ALL (22) . However, in the DLBCL cell lines studied here, c-MYC status (activated by an translocation t (8;14) in Ramos and DHL10, or wild-type in Ly1, Ly3, DHL6)(23, 24) appear to not segregate with the degree of GC sensitivity. PDE4B and AKT are central regulators of glucocorticoid sensitivity in DLBCL. The data above defined an association between PDE4B expression and GC sensitivity, which related to cAMP-mediated inhibition of AKT/mTOR. To move beyond these correlative analyses, and firmly establish the roles of PDE4B and AKT in regulating GC response in B cell lymphomas, we generated DLBCL models stably expressing PDE4B (wild-type, WT, and phosphodiesterase inactive mutant, PI) or a constitutively-active (myristoylated) AKT protein (CA-AKT). We found that reconstitution of PDE4B-WT expression in the PDE4B-null and GC sensitive DHL6 AKT/mTOR phosphorylation, whereas these effects were preserved in PI-mutant expressing cells ( Figure 2B ). Furthermore, we show that cAMP, in a PDE4B and AKT dependent manner also inhibits the expression of MCL1 ( Figure 2B ). These data agree with a previous observation that placed MCL1 downstream to AKT in regulating GC resistance in ALL (14) , but they also highlight the novel role of cAMP/PDE4B in controlling these events. Together, our data suggest that high PDE4B expression in B cell lymphomas contributes to GC resistance by blocking cAMP inhibitory effect on the AKT/mTOR pathway and its downstream components.
Since AKT has broad activities, we found necessary to establish that in the present context its 
exposure to forskolin, cAMP levels were similarly raised in the PDE4B-PI and CA-AKT cells, despite the fact that the latter were resistant to cAMP-controlled GC sensitization, and in both cases at significantly higher levels than in the PDE4B-WT expressing cells (p<0.05, one way ANOVA test, Supplementary Figure 2A) ; these data demonstrate that AKT does not interfere with the generation of cAMP. Next, we examined whether the previously reported link between induction of glucocorticoid-receptor (GR) expression by cAMP and restoration of GC sensitivity (25, 26) accounted for our results. Here, we tested if CA-AKT expression was interfering with cAMP-mediated GR regulation. Our data showed that despite being resistant to cAMP-controlled GC sensitization, in the CA-AKT lymphoma cells GR expression was promptly induced by this cAMP (Supplementary Figure 2B) . Finally, we showed that the GC resistance acquired by the CA-AKT expressing cells was not a general growth advantage phenomenon; in these assays we found that in the absence of cAMP, CA-AKT lymphomas proliferated at the same rate, and responded to dexamethasone in the same manner as their isogenic counterparts expressing PDE4B-WT and -PI cells (Supplementary Figure 2C) .
Taken together, these results establish PDE4B as an important regulator of GC efficacy in lymphomas, indicate that a functional AKT pathway is critical for the cAMP/PDE4B-controlled restoration of GC activity, and demonstrate that induction of GR expression does not fully account for the improved GC response that follows PDE4B inhibition/cAMP elevation in lymphocytes. 
In vitro:
Up to this point we have used genetic models of PDE4B gain of function to establish the role of this enzyme in controlling GC responses in B cell lymphomas. However, our ultimate objective is to test in the clinic the potential of pharmacological PDE4B inhibition as a rational strategy to reverse GC resistance in lymphoid malignancies. To start to address this translational aspect of our research, we examined the effects of rolipram, a prototypical PDE4 inhibitor(13), in three independent GC-resistant lymphoma cell lines that express high levels of PDE4B. In Figure 3B) . Demonstrating the specificity of these effects, exposure to rolipram was accompanied by elevation of intracellular levels of cAMP (Supplementary Figure 3C) but did not impact on the effectiveness of two broad-spectrum chemotherapeutic agents (Supplementary Figure 3D) . Finally, confirming the central role of PDE4B in regulating cAMP effects towards AKT/mTOR, and on the relevance of this pathway in controlling GC sensitivity in B cell lymphomas, rolipram treatment was accompanied by a decrease in the phospho levels of AKT, S6K and 4EPB1 ( Figure 3D ). Figures 3E-F) and more importantly became sensitive to dexamethasone activity (Figures 3E). Of note, using multiple RNAi strategies we were consistently unable to isolate stable polyclonal or monoclonal B cell populations displaying a substantial knockdown of PDE4B expression (e.g., > 80%), and only those cells with more modest downregulation of this gene (~40%) were rescued for downstream experiments. We attribute these findings to the addiction of B lymphoma cells to low level of cAMP, and loss of viability with continuous suppression of this gene. Nonetheless, even though in the cell populations that we analyzed the shRNA effects on PDE4B expression were only moderate (Supplementary Figure 3E) , they readily led to increase in intracellular cAMP levels (Supplementary Figure 3F) , and improvement in dexamethasone activity ( Figure   3E ).
In vivo:
To determine whether PDE4 inhibition could also reverse GC resistance in a more relevant setting, we tested the efficacy of dexamethasone, rolipram or their combination for the treatment of a xenograft model of human lymphoma with non-invasive luminescent imaging capability. In these assays, the mice were inoculated subcutaneously with the aggressive B cell lymphoma cell line Ramos (PDE4B-high, GC-resistant) constitutively expressing the luciferase gene. Seventy-two hours after tumor implantation, the mice were imaged, assigned to distinct treatment group and followed weekly with luminescence imaging. Consistent with our in vitro results, within 2-3 weeks of treatment, mice from two independent cohorts which received PDE4B expression and AKT activity in primary DLBCLs. Using in silica investigations, and in vitro and in vivo studies in lymphoma cell lines, we mechanistically defined a novel interplay between PDE4B-controlled cAMP effects and AKT/mTOR activities, with major relevance for GC sensitivity. As a next step in our investigation, we aimed to confirm that this cross-talk is also present in primary lymphoma samples. This is also relevant because it could start to establish the potential of PDE4B measurements in association with AKT/mTOR activity, in the design of biomarker-guided trials aimed at restoring GC response in B cell malignancies. To achieve these goals, we recently identified a collection of primary DLBCL and obtained enough good quality matching RNA and protein from a subset of tumors (n=15). Table 3 ), a methodology that we have extensively shown to correlate with this enzyme's activity (9, 11) , and phospho-AKT and phospho-S6K levels were determined by Western blot. In agreement with our cell lines data, a significantly higher expression of these phospho-proteins was found in primary DLBCL expressing high levels of PDE4B (p<0.05, Mann-Whitney test for the densitometric values -normalized by two independent control proteins, β-actin and α-tubulin), thus suggesting that the cAMP/PDE4B axis could play a role in controlling this oncogenic pathway in primary DLBCL ( Figure 5 ). 
DISCUSSION
The mechanistic basis for GC resistance in B-cell tumors remains ill defined. Early investigations had tentatively linked this event to loss-of-function mutation, defective expression or specific promoter usage of the glucocorticoid receptor (GR) gene (27, 28) . However, studies in large and well characterized ALL cohorts did not confirm these hypotheses (29, 30) .
Interestingly, cAMP has long been known to modulate GR expression, and initial studies suggested that the benefits of this second messenger on GC sensitivity were related to GR induction (25) . Still, we found that although GR expression in DLBCL is indeed induced by cAMP, it did not influence GC sensitivity. Rather, we demonstrated that the cAMP-mediated inhibition of AKT/mTOR is the central event needed to reinstate GC sensitivity in B-cell lymphomas. Additional studies will ascertain whether the cAMP-mediated induction of GR expression could also play role in the down-modulation of AKT/mTOR functions. In fact, our results agree with recent reports implicating this pathway in GC-resistant ALL (14) , but refine the picture by showing that PDE4B is an important upstream regulator of AKT activity in this context. Downstream to AKT/mTOR, the anti-apoptotic protein MCL1 has been suggested to be a predictor of GC resistance in MLL-rearranged infant acute lymphoblastic leukemia (21) . Our preliminary data in DLBCL did not find a correlation between baseline MCL1 levels and GC response, albeit cAMP lowered MCL1 levels in an AKT dependent manner. The reason for this discrepancy is presently unclear but it could reflect the distinct biology of immature (ALL) and 
Together, our data show that modulation of cAMP levels, primarily via inhibition of phosphodiesterase, should be clinically tested for the treatment of lymphoid malignancies. In particular, our data highlight the role of PDE4 inhibitors in restoring GC sensitivity and demonstrate that insights into disease pathogenesis can be exploited not only to identify novel targets for treatment, but also to rationally overcome resistance to classical pharmacological agents. It is possible that further elucidation of the cAMP effects on B cells, in particular the events upstream to SYK and PI3K/AKT(9, 11), will improve our appreciation of the role of this second messenger in B cell biology, and create novel opportunities for the development of therapeutic strategies in malignant, inflammatory and auto-immune conditions.
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